

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Jing S. Belfield

Type or print name

Self Zell

10/03

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

QUAN ET AL.

APPLICATION NO: 10/602,214

FILED: JUNE 24, 2003

FOR:

Mailstop: DD

Commissioner for Patents Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/099,358, now U.S. Patent 6,339,099, filed June 18, 1998, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Jing S. Belfield, Ph.D.

Agent for Applicants

Reg. No. 45,914

Bristol-Myers Squibb Company Patent Department P.O. Box 4000 Princeton, NJ 08543-4000 (609) 252-3791

Date: 9/10/03

Please type a plus sign (+) inside this box

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

work Reduction Act of the no persons are required to respond to a coffection of information unless it contains a valid OMR control number.

Substitute for form 1448A/PTO

SEP 1 2 2003

INFORMATION DISCLOSURE STATEMENT BY ARBUCANT

(use as many sheets as necessary)

Sheet 1 of 2

ic reduced in leabolin in a collection of	The Hallott unitess it contains a valid OMB con	rol number.
	Complete if Known	
Application Number	10/602,214	
Filing Date	6/24/03	· · · · · · · · · · · · · · · · · · ·
First Named Inventor	Quan et al.	
Group Art Unit		
Examiner Name	Unknown	
Attorney Docket Number	DM-6904 CNT 2	

	,			U.S. PATENT DOCUM	MENTS	
Francisco.		U.S. Patent Doo	ument	Name of Patentee or Applicant	Date of Publication of	Barra Calarra III and a
Examiner initials •	Cite No.1	Number Kind Code ² (If known)		of Cited Document	Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevan Passages or Relevant Figures Appear
		5,202,330	Α	E. R. Squibb & Sons, Inc.	4/13/1993	
		5,317,103	А	Merck Sharp & Dohme Limited	5/31/1994	
		5,342,851	Α	McNeil-PPC, Inc.	8/30/1994	
		5,463,071	Α	Dr. Karl Thomae GmbH	10/31/1995	
	<u> </u>	5,616,601	A	GD Searle & Co	4/1/1997	
		5,681,838	A	Hoechst AG	10/28/1997	
		5,707,998	Α	Eisai Co., Ltd.	1/13/1998	
		6,020,357	Α	DuPont Pharma. Company	2/1/2000	

V,

<u> </u>	, ———				N PATENT DOCU	MENTS		
Examiner Cite	Cite No.1		eign Patent Doc	ument i	Name of Patentee or Applicant of	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	
	110.	Office ³	Number ⁴	(if known)	Cited Document	MM-DD-YYYY	Passages or Relevant Figures Appear	Te
		wo	9402477	A	Merck Sharp & Dohme Limited	2/3/1994		
		wo	9514683	A	DuPont Merck Pharma. Company	6/1/1995		
		wo	9518111	A	DuPont Merck Pharma. Company	7/6/1995	į	
		wo	9628427	A	Berlex Lab., Inc.	9/19/1996		
		wo	9640143	A	SmithKline Beecham Corporation	12/19/1996		
		wo	9723212	A.	DuPont Merck Pharma. Company	7/3/1997		
		wo	9732583	A	SmithKline Beecham Corporation	9/12/1997		

	Name and Address of the Owner, where the Owner, which is the Owner, where the Owner, which is the Owner, where the Owner, which is the Owner		
Examiner	. , ,	Date	
Signature	1		
Uigitatu	<u></u>	Considered	1
			1

EXAMINER: Initial if reference considered, whether or not cliation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbots as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark hee if English language Translation is attached.

PI6888	type a plus sign (+) inside this box	≥ +	•
	016	73.	

of 2

Sheet

2

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

DM-6904 CNT 2

Under the Paperwork Reduction Act of 1956 No person	ns are required to respond to a collection	of Information unless it contains a valid OMB control number.
Substitute for form 1449A/PTQ		Compl te if Known
\-	Application Number	10/602,214
INFORMATION DISCLOSURE	Filing Date	6/24/03
STATEMENT BY APPLICANT	First Named Inventor	Quan tal.
MADE	Group Art Unit	1624
INFORMATION CISCLOSURE STATEMENT BY APPLICANT First Named Inventor Quan tal.	Unknown	

Attorney Docket Number

				FOREIG	N PATENT DOCU	MENTS		
Superings	Cite	Foreign Patent Document		Name of Patentee	Date of Publication of	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear	T ₆
		EP	234830	A	E. R. Squibb & Sons, Inc.	9/2/1987		
		EP	236902	A	E. R. Squibb & Sons, Inc.	9/16/1987		
		EP	513387	В	Otsuka Pharm. Co.	11/19/1992		
		E P	554829	Α	Fujisawa Pharm. Co.	8/11/1993		
		JP	4247081	A	Takeda Chem. Ind. Ltd.	9/3/1992	Chemical Abstract	
				!				
				4				
				lų .		<u> </u>		
				4		ĺ		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		TIDWELL et al. "Diarylamidine derivatives with one or both of the aryl moleties consisting of an indole or indole- like ring. Inhibitors of arginine-specific esteroproteases", J. Med. Chem. (1978), 21(7), 613-623.	
		: : ij	

	· ·		
	,		1 '
Everniner	1	Date	<u> </u>
Examiner	<u> </u>	1 0410	1
01	· ,	Considered	
Signature	1	Considered	

EXAMINER: Initial if reference considered, whether or not clighton is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE persons are required to respond to a collection of information unless it contains a valid OMB control number. Under the Pa

SEP 1 2 2003 Substitute for form 1449A/PT INFORMATION DESCLOS

STATEMENT BY APPECAN

(use as many sheets as necessary)

Sheet of 2

Please type a plus sign (+) inside this

	Complete if Known	
Application Number	10/602,214	
Filing Date	6/24/03	
First Named Inventor	Quan et al.	
Group Art Unit		
Examiner Name	Unknown	
Attorney Docket Number	DM-6904 CNT 2	

				U.S. PATENT DOCUM	TENTS	
Eveniner		U.S. Patent Doc	ument	Name of Patentee or Applicant	Date of Publication of	Pages, Columns, Lines, Where Relevant
Examiner Initials *	Cite No.1	Number Kind (of Cited Document	Cited Document MM-DD-YYYY	Passages or Relevant Figures Appear
		5,202,330	Α	E. R. Squibb & Sons, Inc.	4/13/1993	
		5,317,103	Α	Merck Sharp & Dohme Limited	5/31/1994	
		5,342,851	Α	McNeil-PPC, Inc.	8/30/1994	
		5,463,071	Α	Dr. Karl Thomae GmbH	10/31/1995	
		5,616,601	Α	GD Searle & Co	4/1/1997	
		5,681,838	Α	Hoechst AG	10/28/1997	
		5,707,998	Α	Eisai Co., Ltd.	1/13/1998	
		6,020,357	Α	DuPont Pharma. Company	2/1/2000	

				FOREIG	N PATENT DOCU	MENTS		
F. cominan	Cite	Foreign Patent Document			Name of Patentee	Date of Publication of	Pages, Columns, Lines,	
Examiner Initials*	No.1	Office ³		Kind Code ⁵ (<i>if known</i>)	or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	T ₆
		wo	9402477	Α	Merck Sharp & Dohme Limited	2/3/1994		
		wo	9514683	А	DuPont Merck Pharma. Company	6/1/1995		
		wo	9518111	А	DuPont Merck Pharma. Company	7/6/1995		
		wo	9628427	А	Berlex Lab., Inc.	9/19/1996		
		wo	9640143	А	SmithKline Beecham Corporation	12/19/1996		
		wo	9723212	А	DuPont Merck Pharma. Company	7/3/1997		
		wo	9732583	А	SmithKline Beecham Corporation	9/12/1997		

Examiner	Date
Signature	Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark hee if English language Translation is attached.

Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1959 to persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTØ INFORMATION BISC

STATEMENT BY APRI

(use as many sheets as necessary)

Sheet of

	Complete if Known		
Application Number	10/602,214		
Filing Date	6/24/03		
First Named Inventor	Quan et al.		
Group Art Unit	1624		
Examiner Name	Unknown		
Attorney Docket Number	DM-6904 CNT 2		

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆	
		EP	234830	А	E. R. Squibb & Sons, Inc.	9/2/1987		
		EP	236902	Α	E. R. Squibb & Sons, Inc.	9/16/1987		
		EP	513387	В	Otsuka Pharm. Co.	11/19/1992		
		EP	554829	Α	Fujisawa Pharm. Co.	8/11/1993		
		JP	4247081	А	Takeda Chem. Ind. Ltd.	9/3/1992	Chemical Abstract	

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *				
		TIDWELL et al. "Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole-like ring. Inhibitors of arginine-specific esteroproteases". J. Med. Chem. (1978), 21(7), 613-623.		

Examiner	Date		Ì
Signature	Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.